Sheet	1	of	1
0.,00.		•	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COI		50026/052001
(MODIFIED) PATENT AND TRADEMARK	Serial No.	10/532,172
	Applicant	OKANO et al
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	371(c) Date	August 29, 2005
(Use several sheets if necessary)	Group	1653
(37 C.F.R. § 1.98(b))	IDS Filed	March 7, 2008

			U.S. PAT	ENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant		Class	Subclass	Filing Date (If Appropriate)
				44.50			
	FORE	IGN PATENT (OR PUBLI	SHED FOREIGN PATEN	T APPLICATIO	DN .	
Examiner's Initials	Document Number	Publication Date		Country or Patent Office	Class	Subclass	Translation (Yes/No)
IP	WO 03/095663	November 20), 2003	WIPO			
	OTHER DOC	JMENTS (INCL	.UDING AI	JTHOR, TITLE, DATE, P	LACE OF PUB	ILICATION)	
IP	European Search	Report for PC	T/JP03/13	476 (Mailed 6 February 2	006)		
			·				

EXAMINER	/Ileana Popa/	DATE CONSIDERED	05/07/2006
EXAMINER: Initial cl	itation considered. Draw line through clommunication to applicant.	tation If not in conformance and no	ot considered. Include copy of this

				,		1	Sheet 1 o
	FORM PTO-1449		NT OF COMMERCE	Attorney D	ocket No.	50026/05	2001
(MODIFIED) PATENT AND TRADEMARK OFF		RADEMARK OFFICE	Serial No.		10/532,17	2	
	***************************************			Applicant		Okano et	ał.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date		April 21, 2	005		
	(Use several si	neets if necessary;	•	Group		Not Yet A	ssigned
37 C.F.R. §	1.98(b))			IDS Filed		ОСТОВЕ	R 7, 2005
		U.S	. PATENT DOCUMEN	ITS		•	
Examiner's nitials	Document Number	Issue or Publication Date	Patentee or App	blicant	Class	Subclass	Filing Date (If Appropriate)
IP	2002/0098576	Jul. 25, 2002	Nagai et al.				
	2002/0100066 A1	Jul. 25, 2002	Nagai et al.				
	2002/0002143	Jan. 03, 2002	Kano et al.				
	2002/0169306 A1	Nov. 14, 2002	Kitazato et al.				
	2003/0166252 A1	Sep. 4, 2003	Kitazato et al.				
	2003/0170210	Sep. 11, 2003	Masaki et al.				
	2003/0170266 A1	Sep. 11, 2003	Kitazato et al.				
	2003/0170897	Sep. 11, 2003	Imai et al.				
	2004/0121308	Jun. 24, 2004	Nagai et al.				
	2004/0005296	Jan. 08, 2004	Yonemitsu et al.				
	2003/0203489	Oct. 30, 2003	Yonemitsu et al.				
	2004/0053877	Mar. 18, 2004	Fukumura et al.				
	2004/0101965	May 27, 2004	Griesenbach et al.				
	5,962,274	Oct. 5, 1999	Parks		<u> </u>		
	6,040,174	Mar. 21, 2000	Imler et al.				
	6,645,760	Nov. 11, 2003	Nagai et al.				
	6,723,532	Apr. 20, 2004	Nagai et al.				
	6,746,860	Jun. 8, 2004	Tokusumi et al.				
IP	6,828,138	Dec. 7, 2004	Nagai et al.				
	FOREIG	N PATENTS OR F	PUBLISHED FOREIGI	PATENT A	PPLICATIO)NS	
Examiner's Initials	Document Number	Publication Date	Country Patent O		Class	Subclass	Translation (Yes/No)
IP	AU 7335196 A	May 22, 1997	Australia	-			
IP	CA 2236113 A1	May 9, 1997	Canada				
IP	CN 1207123 A, B	Feb. 3, 1999	China				
EXAMINER	/I	leana Popa	DATE C	ONSIDERED	0	5/07/20	06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

<u> </u>	 						T	Sheet 2 of
SUBSTITUTE (MODIFIED)	FORM PTO-1449	U.S. DEPARTMEN' PATENT AND TRA			Attorney Do	ocket No.	50026/05	2001
יייין יייין איייין		OCIVIA (((O)) TO	٦	Serial No.		10/532,17	' 2	
	INFORMATIO	N DISCLOSURE			Applicant		Okano et	al.
	STATEMENT	BY APPLICANT eets if necessary)			Filing Date		April 21, 2	2005
	(OSE SEVERAL SIL	cess ii licocssury,			Group		Not Yet A	ssigned
(37 C.F.R. § 1	.98(b))				IDS Filed		ОСТОВЕ	R 7, 2005
	FOREIGN	PATENTS OR PU	BLISHED FOREI	GN	PATENT AP	PLICATIO	NS	
Examiner's Initials	Document Number	Publication Date			ry or Office	Class	Subclass	Translation (Yes/No)
IP	CN 1357044 A	Jul. 3, 2002	China					No
	EP 0 863 202 A1	Sep. 9, 1998	EPO					
	EP 0 864 645 A1	Sep. 16, 1998	EPO		_			
	EP 1 106 692 A1	Jun. 13, 2001	EPO					
	EP 1 179 594 A1	Feb. 13, 2002	EPO					
	EP 1 325 960 A2	Jul. 9, 2003	EPO					
	HK 1018287 A1	Nov. 21, 2003	Hong Kong					
	JP 7-509616 A1	Oct. 26, 1995	Japan					Claims only
-	JP 10-506542A1	Jun. 30, 1998	Japan					Yes
	WO 97/16171A1	May 9, 1997	WIPO					Abstract only
	WO 97/16538A1	May 9, 1997	WIPO		··· *			Yes
	WO 00/27430A3	May 18, 2000	WIPO					Abstract only
	WO 00/70055	Nov. 23, 2000	WIPO					Yes
	WO 00/70070A1	Nov. 23, 2000	WIPO					Yes
	WO 01/32898A3	May 10, 2001	WIPO					
	WO 03/092738A1	Nov. 13, 2003	WIPO					Yes
	WO 03/093476A1	Nov. 13, 2003	WIPO					Yes
	WO 03/102183A,1	Dec. 11, 2003	WIPO					Yes
	WO 2004/038029A1	May 6, 2004	WIPO					Yes
	OTHER DOCUM	MENTS (INCLUDING	G AUTHOR, TITL	Ε, C	DATE, PLAC	E OF PUB	LICATION)	
	Ali and Nayak, "Asse Tail and Transmemb						ns and with t	he Cytoplasmic
	Altenschmidt et al., "	Specific Cytotoxic T	Lymphocytes In	Ger	ne Therapy,"	J. Mol. Me	d. 75(4):259	-266 (1997).
IP	Auten et al., "Effect of Primary T Cells and	of Scaffold Attachmo Macrophages," Hur	ent Region on Tra m. Gene Ther. 10	nsg 8):1	jene Express 1389-1399 (1	sion in Reti 999).	rovirus Vecto	or-Transduced
EXAMINER	./	/Ileana Popa	a/ DATE	CC	NSIDERED		0!	5/07/2006
EXAMINER: I form with the	nitial citation considere	ed. Draw line through applicant.	gh citation if not in	ω	nformance a	nd not cor	nsidered. Inc	dude copy of this

•

Sheet 3 of 6

			Sheet 3
	FORM PTO-1449 U.S. DEPARTMENT OF COMM		lo. 50026/052001
MODIFIED)	PATENT AND TRADEMARK OF	Serial No.	10/532,172
		Applicant	Okano et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 21, 2005
(Use several sheets if necessary)		Group	Not Yet Assigned
37 C.F.R. §	1.98(b))	IDS Filed	OCTOBER 7, 2005
	OTHER DOCUMENTS (INCLUDING AUTHOR, 1	TITLE, DATE, PLACE OF P	UBLICATION)
IP	Ayuk et al., "Establishment of an Optimised Gene Tran: Clinical Requirements," <i>Gene Ther.</i> 6(10):1788-1792 (1)	sfer Protocol for Human Pri 1999).	mary T Lymphocytes According
	Bagai et al., "Hemagglutinin-Neuraminidase Enhances Sendai Virus Envelopes with Cells," J. Virol. 67(6):3312	F Protein-Mediated Membr 2-3318 (1993).	rane Fusion of Reconstituted
	Barclay and Palese, "Influenza B Viruses with Site-Spe 69(2):1275-1279 (1995).	cific Mutations Introduced i	nto the HA Gene," J. Virol.
	Bitzer et al., "Sendai Virus Efficiently Infects Cells via to of Cleaved Fo Precursor Proteins for this Alternative Ro	ne Asialoglycoprotein Receptute of Cell Entry," J. Virol.	ptor and Requires the Presence 71(7):5481-5486 (1997).
	Blaese et al., "T Lymphocyte-Directed Gene Therapy fo 270(5235):475-480 (1995).	or ADA ⁻ SCID: Initial Trial Re	esults After 4 Years," Science
	Brenner, "Gene Transfer to Hematopoietic Cells," New	Eng. J. Med. 335(5):337-33	39 (1996).
	Brown and Rose, "Sorting of GPI-Anchored Proteins to Transport to the Apical Cell Surface," Cell 68(3):533-54	Glycolipid-Enriched Memb 44 (1992).	rane Subdomains during
	Buchschacher and Wong-Staal, "Development of Lenti 95(8):2499-2504 (2000).	iviral Vectors for Gene Ther	apy for Human Diseases," <i>Bloo</i>
	Bunnell et al., "Efficient In Vivo Marking of Primary CD- Ape Leukemia Virus-Derived Retroviral Vector," <i>Blood</i>	4+ T Lymphocytes in Nonhu 89(6):1987-1995 (1997).	uman Primates Using a Gibbon
	Cathomen et al., "A Matrix-Less Measles Virus Is Infec Propagation in the Brain," <i>EMBO J.</i> , 17(14):3899-3908	tious and Elicits Extensive (1998).	Cell Fusion: Consequences for
	Conzelmann, "Nonsegmented Negative-Strand RNA V Rev. Genet., 32:123-162 (1998).	iruses: Genetics and Manip	oulation of Viral Genomes," Ann
	Costello et al., "Gene Transfer into Stimulated and Uns Vectors," Gene Ther. 7(7):596-604 (2000)	stimulated T Lymphocytes b	y HIV-1-Derived Lentiviral
	Dardalhon et al., "Lentivirus-mediated Gene Transfer in Ther. 8(3):190-198 (2001)	n Primary T Cells Is Enhand	ced by a Central DNA Flap," Ge
	Di Nicola et al., "Recombinant Adenoviral Vector-Lipofi Lymphocytes," <i>Hum. Gene Ther.</i> 10(11):1875-1884 (19	ectA MINE Complex for Ge 999).	ne Transduction into Human T
	Douglas et al., "Targeted Gene Delivery by Tropism-M 1578 (1996).	odified Adenoviral Vectors,	* Nat. Biotechnol. 14(11):1574-
	Friedman, "Expression of Human Adenosine Deamina Proc. Natl. Acad. Sci. USA 82(3):703-707 (1985).	se Using a Transmissable I	Murine Retrovirus Vector Syster
	Garoff et al., "Virus Maturation by Budding," Microbiol.	Mol. Biol. Rev., 62(4):1171	-1190 (1998).
IP	Gitman et al., "Use of Virus-Attached Antibodies or Ins Envelopes and Neuraminidase-Treated Cells," <i>Bioche</i>	ulin Molecules to Mediate F mistry 24(11):2762-2768 (1	Fusion Between Sendai Virus 985).
EXAMINER	/Ileana Popa/ D	ATE CONSIDERED	05/07/2006

Sheet 4 of 6

				Sheet 4 o		
	FORM PTO-1449 U.S. DEPARTMENT OF COMM	MERCE	Attomey Docket No.	50026/052001		
(MODIFIED)	PATENT AND TRADEMARK O	OFFICE	Serial No.	10/532,172		
			Applicant	Okano et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		l	Filing Date	April 21, 2005		
	(Use several sheets if necessary)		Group	Not Yet Assigned		
(37 C.F.R. §	1.98(b))		IDS Filed	OCTOBER 7, 2005		
	OTHER DOCUMENTS (INCLUDING AUTHOR,	TITLE, DA	ATE, PLACE OF PUBLI	CATION)		
IP	Gladow et al., "MLV-10A1 Retrovirus Pseudotype Effic Gene Med. 2(6):409-415 (2000).	ciently Tra	nsduces Primary Huma	in CD4 ⁺ T Lymphocytes," J.		
	Hasan et al., "Creation of an Infectious Recombinant S 3' Proximal First Locus," J. Gen. Virol., 78(Pt 11):2813			ly Luciferase Gene from the		
	Hege and Roberts, "T-Cell Gene Therapy," Curr. Opin	n. Biotechr	nol. 7(6):629-634 (1996)).		
	Heggeness et al., *In Vitro Assembly of the Nonglycos Acad. Sci. USA,* 79(20):6232-6236 (1982).	sylated Me	mbrane Protein (M) of	Sendai Virus," <i>Proc. Natl.</i>		
	Huntley et al., "Phosphorylation of Sendai Virus Phosp 272(26):16578-16584 (1997).	phoprotein	by Cellular Protein Kin	ase C ζ," J. Biol. Chem.		
	Ikeda et al. "Recombinant Sendai Virus-Mediated Gen Transfer by Brief Exposure," Exp. Eye Res. 75(1):39-4			Tissue: Efficient Gene		
	Imbert et al., "Highly Efficient Retroviral Gene Transfel Blood," Cancer Gene Ther. 1(4):259-265 (1994).	er into Hum	nan Primary T Lymphod	ytes Derived from Periphera		
	Inoue et al., "A New Sendai Virus Vector Deficient in the Extensive Cell-to-Cell Spreading," <i>J. Virol.</i> 77(11):641	the Matrix 19-6429 (2	Gene Does Not Form V 003).	firus Particles and Shows		
	Karron et al., "Respiratory Syncytial Virus (RSV) SH at Clinical Evaluation and Molecular Characterization of Proc. Natl. Acad. Sci. USA 94(25):13961-13966 (1997)	a Cold-Pa	eins Are Not Essential (ssaged, Attenuated RS	for Viral Replication <i>In Vitr</i> o: SV Subgroup B Mutant,"		
	Kato et al., "Initiation of Sendai Virus Multiplication fro Sense," Genes Cells, 1(6):569-579 (1996).	om Transfe	ected cDNA or RNA with	n Negative or Positive		
	Kido et al., "The Human Mucus Protease Inhibitor and Infection with Influenza A and Sendai Viruses," Biopole	d its Mutar alymers (Pe	nts Are Novel Defensive eptide Science) 51(1):7	Compounds Against 9-86 (1999).		
	Kondo et al., "Temperature-Sensitive Phenotype of a Accumulation of the M Protein," J. Biol. Chem. 268(29)	Mutant Se 9):21924-2	endai Virus Strain Is Ca 21930 (1993).	used by its Insufficient		
	Kühlcke et al., "Highly Efficient Retroviral Gene Transfer Based on Centrifugation-Mediated Vector Preloading of Tissue Culture Vessels," <i>Mol. Ther.</i> 5(4):473-478 (2002).					
	Lamb and Kolakofsky, "Paramyxoviridae: The Viruses and Their Replication," Fields Virology, 3 rd ed., B.N. Fields et at., Lippincott-Raven Publishers, Philadelphia, Chapter 40, p. 1181 (1996).					
	Leyrer et al., "Sendai Virus-Like Particles Devoid of Haemagglutinin-Neuraminidase Protein Infect Cells Via the Human Asialoglycoprotein Receptor," <i>J. Gen. Virol.</i> 79(Pt. 4):683-687 (1998).					
	Li et al., "A Cytoplasmic RNA Vector Derived from No Expression," J. Virol. 74(14):6564-6569 (2000).	ontransmis	sible Sendai Virus with	Efficient Gene Transfer and		
IP	Lin et al., "The RNA Binding Region of the Paramyxov	virus SV5	V and P Proteins," Viro	logy 238(2):460-469 (1997)		
EXAMINER	/Ileana Popa/ t	DATE CO	NSIDERED	05/07/2006		
EXAMINER:	Initial citation considered. Draw line through citation if exect communication to applicant.	not in con	nformance and not cons	sidered. Include copy of this		

Sheet 5 of 6

			Sheet 5 o			
	E FORM PTO-1449 U.S. DEPARTMENT OF COMMERC		50026/052001			
(MODIFIED)	PATENT AND TRADEMARK OFFIC	E Serial No.	10/532,172			
	111707111710117101171	Applicant	Okano et al.			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	April 21, 2005			
	(Use several sheets if necessary)	Group	Not Yet Assigned			
(37 C.F.R. §	1.98(b))	IDS Filed	OCTOBER 7, 2005			
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITL	E, DATE, PLACE OF PUBL	ICATION)			
IP	Maniè et al., "Measles Virus Structural Components Are Er Location for Virus Assembly," J. Virol. 74(1):305-311 (2000		domains: A Potential Cellula			
	Markwell et al., "An Alternative Route of Infection for Viruse a Sendai Virus Mutant Lacking its Attachment Protein," Pro					
	Matsumura et al., "RNA Editing-Like Phenomenon in Parar Infected With a Recombinant Baculovirus," J. Gen. Virol. 8	nyxovirus V Gene mRNA O)(Pt. 1):117-123 (1999).	bserved in Insect Cells			
	Mebatsion et al., "Matrix Protein of Rabies Virus Is Respon Particles and Interacts with the Transmembrane Spike Gly					
	Misaki et al., "Gene-Transferred Oligodonal T Cells Predor Deaminase-Deficient Patient During Gene Therapy," Mol. 1	ninantly Persist in Periphera Ther. 3(1):24-27 (2001).	al Blood From an Adenosine			
	Miura et al., "HVJ (Sendai Virus)-Induced Envelope Fusion Protein Antibody That Does Not Inhibit Hemagglutination A	and Cell Fusion Are Blocke ctivity of HVJ," Exp. Cell Re	ed by Monoclonal Anti-HN s. 141(2):409-420 (1982).			
	Monkawa et al., "Characterization of Temperature-Sensitiv 64(1):15-30 (1991).	Mutants of Measles Virus	," Kitasato Arch. of Exp. Med			
	Movassagh et al., "Retrovirus-Mediated Gene Transfer into Vitro Selection," Hum. Gene Ther11(8):1189-1200 (2000)		Efficiency Without Further I			
	Nagai, "Paramyxovirus Replication and Pathogenesis. Rev Virol. 9(2):83-99 (1999).	erse Genetics Transforms (Inderstanding," Rev. Med.			
	Okano et al., "Recombinant Sendai Virus Vectors for Activa (2003).	ted T Lymphocytes," Gene	Ther. 10(16):1381-1391			
	Pollok et al., "High-Efficiency Gene Transfer into Normal ar Mediated by Transduction on Recombinant Fibronectin Fra					
	Ponimaskin et al., "Sendai Virosomes Revisited: Reconstit Gene Transfer," Virology 269(2):391-403 (2000).	tion with Exogenous Lipids	Leads to Potent Vehicles fo			
	Puls and Minchin, "Gene Transfer and Expression of a Nor Ther. 6(10):1774-1778 (1999)	-Viral Polycation-Based Ve	ctor in CD4 ⁺ Cells," Gene			
	Ramani et al., "Novel Gene Delivery to Liver Cells Using Engineered Virosomes," FEBS Lett. 404(2-3):164-168 (1997).					
	Rosenberg et al., "Gene Transfer Into Humans-Immunothe Turnor-Infiltrating Lymphocytes Modified by Retroviral Gen					
	Rudoll et al., "High-Efficiency Retroviral Vector Mediated G Lymphocytes," <i>Gene Ther</i> . 3(8):695-705 (1996).	ene Transfer into Human P	eripheral Blood CD4 ⁺ T			
7.	Sakai et al., "Accommodation of Foreign Genes into the Se Replication," FEBS Lett. 456(2):221-226 (1999).	ndai Virus Genome: Sizes	of Inserted Genes and Viral			
IP						

Sheet 6 of 6

			Sheet 6			
	E FORM PTO-1449 U.S. DEPARTMENT OF COMME		50026/052001			
(MODIFIED)	PATENT AND TRADEMARK OF	Serial No.	10/532,172			
INFORMATION DISCLOSURE		Applicant	Okano et al.			
	STATEMENT BY APPLICANT	Filing Date	April 21, 2005			
	(Use several sheets if necessary)	Group	Not Yet Assigned			
37 C.F.R. §	1.98(b))	IDS Filed	OCTOBER 7, 2005			
	OTHER DOCUMENTS (INCLUDING AUTHOR, TI	TLE, DATE, PLACE OF PUB	LICATION)			
IP	Sanderson et al., "Sendai Virus Assembly: M Protein Bir Pathway," J. Virol. 67(2):651-663 (1993).	nds to Viral Glycoproteins in 1	Fransit through the Secretory			
	Sanderson et al., "Sendai Virus M Protein Binds Indeper Virol. 68(1):69-76 (1994).	ndently to Either the F or the	HN Glycoprotein <i>In Vivo</i> ,⁴ <i>J</i> .			
	Schwartz et al., "Synthetic DNA-Compacting Peptides D Mediated Gene Transfer In Vitro and In Vivo," Gene The		e Enhance Cationic Lipid-			
	Shiotani et al. "Skeletal Muscle Regeneration After Insul Sendai Virus Vector," <i>Gene Ther.</i> 8(14):1043-1050 (200		Transfer by Recombinant			
	Simons and Ikonen, "Functional Rafts in Cell Membrane	es," Nature 387(6633):569-57	2 (1997).			
	Spielhofer et al., "Chimeric Measles Viruses with a Fore	ign Envelope," J. Virol. 72(3)	2150-2159 (1998).			
	Stockschläder et al., "Expansion and Fibronectin-Enhan Lymphocytes for Adoptive Immunotherapy," J. Hematoth	ced Retroviral Transduction of the Stem Cell Res. 8(4):401-4	of Primary Human T 10 (1999).			
	Stricker and Roux, "The Major Glycoprotein of Sendai V Gen. Virol. 72(Pt. 7):1703-1707 (1991).	irus Is Dispensable for Efficie	ent Virus Particle Budding," J			
	Thompson and Portner, "Localization of Functional Sites Sendai Virus by Sequence Analysis of Antigenic and Te					
	Tomasi et al., "Conjugation of Specific Antibodies to Ser	ndai Virus Particles," FEBS L	ett. 143(2):252-256 (1982).			
	Tuffereau et al., "The Role of Haemagglutinin-Neuramin of Sendai Virus-Infected BHK-21 Cells," <i>J. Gen. Virol.</i> 66	idase Glycoprotein Cell Surfa 6(11):2313-2318 (1985).	ace Expression in the Surviva			
	Tuohy and Mathisen, "T Cell Design for Therapy in Auto 226-232 (2000).	immune Demyelinating Disea	ase," J. Neuroimmunol. 107(2			
	Uchida et al., "High Efficiency Gene Transfer into Murine 136(5):1876-1879 (1986).	T Cell Clones Using a Retro	oviral Vector," J. Immunol.			
	Wickham et al., "Targeted Adenovirus-Mediated Gene C (1997).	Delivery to T Cells Via CD3," .	J. Virol. 71(10):7663-7669			
	Yonemitsu et al., "Efficient Gene Transfer to Airway Epithelium Using Recombinant Sendai Virus," Nat. Biotechnol. 18(9):970-973 (2000).					
	Yoshida et al., "Membrane (M) Protein of HVJ (Sendai \ (1976).	'irus): Its Role in Virus Assen	nbly," <i>Virology</i> 71(1):143-161			
	Yu et al., "Sendai Virus-Based Expression of HIV-1 gp1: 2:457-466 (1997).	20: Reinforcement by the V(-	Version," Genes to Cells			
IP	Zhirnov, "Solubilization of Matrix Protein M1/M from Vino Paramyxoviruses," <i>Virology</i> 176(1):274-279 (1990).	ons Occurs at Different pH fo	r Orthomyxo- and			
XAMINER	/Ileana Popa/ DA	TE CONSIDERED	05/07/2006			